Animal Studies

该项目将利用旧项目 1 中开发的技术来量化啮齿动物的葡萄糖氧化和脂肪酸代谢。该项目将利用老鼠（ZDF Zucker）和糖尿病小鼠模型（MHC-PPAR 或 MCK-PPAR），在这些控制良好的模型中评估糖尿病动物和正常对照之间代谢特征的差异，以及仪器项目中在人类中使用的疗法的效果。动物模型的一个重要优点是能够评估遗传变化对心脏代谢和这些疗法产生的其他组织的影响。该项目还将利用动物模型来验证放射性药物 在项目 1 中开发。因此，该项目将与其他两个项目交互。的 用于代谢研究的放射性药物将在回旋加速器/放射化学核心中生产，该项目将利用仪器核心中所采用的 microPET 技术的进步。该项目将解决一个普遍的假设，即心脏病的啮齿动物模型与 microPET 和 microCT 成像相结合，可用于评估疾病的代谢变化以及药物治疗引起的变化。对此 我们的目标是评估三种糖尿病模型和选定的疗法。

This project will take advantage of the techniques developed in old Project 1 to quantify glucose oxidative and fatty acid metabolism in the rodent. The project will utilize both rat (ZDF Zucker) and mouse models (MHC-PPAR or MCK-PPAR) of diabetes to evaluate in these well controlled models, the differences in metabolic profile between diabetic animals and normal controls as well as the effect of the therapies being utilized in humans in the instrumentation project. An important advantage of the animal model is the ability to evaluate the impact that genetic changes have on cardiac metabolism and other tissues resulting from these therapies. This project will also utilize animal models to validate the radiopharmaceuticals being developed in Project 1. The project will, therefore, interact with both other projects. The radiopharmaceuticals for the metabolism studies will be produced in the cyclotron/radiochemistry core and this project will take advantage of the advances in microPET technology being carried out in the instrumentation core. This project will address the general hypothesis that rodent models of cardiac disease in conjunction with microPET and microCT imaging can be used to evaluate metabolic changes in the disease as well as changes caused by drug therapies. To this aim we will evaluate three models of diabetes and selected therapies.